nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—HTR2C—Sorafenib—thyroid cancer	0.0922	0.235	CbGbCtD
Ziprasidone—CYP3A7—Sorafenib—thyroid cancer	0.0601	0.153	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0601	0.153	CbGbCtD
Ziprasidone—CYP3A5—Sorafenib—thyroid cancer	0.0451	0.115	CbGbCtD
Ziprasidone—CYP1A2—Sorafenib—thyroid cancer	0.0336	0.0854	CbGbCtD
Ziprasidone—CYP3A4—Vandetanib—thyroid cancer	0.0292	0.0742	CbGbCtD
Ziprasidone—CYP2D6—Sorafenib—thyroid cancer	0.0277	0.0704	CbGbCtD
Ziprasidone—CYP3A4—Sorafenib—thyroid cancer	0.0176	0.0448	CbGbCtD
Ziprasidone—CYP2D6—Doxorubicin—thyroid cancer	0.0168	0.0427	CbGbCtD
Ziprasidone—CYP3A4—Doxorubicin—thyroid cancer	0.0107	0.0272	CbGbCtD
Ziprasidone—H1F0—neck—thyroid cancer	0.00269	0.0551	CbGeAlD
Ziprasidone—H1F0—saliva-secreting gland—thyroid cancer	0.0021	0.043	CbGeAlD
Ziprasidone—HTR1E—head—thyroid cancer	0.00192	0.0394	CbGeAlD
Ziprasidone—CHRM4—head—thyroid cancer	0.00169	0.0345	CbGeAlD
Ziprasidone—HTR7—neck—thyroid cancer	0.00166	0.034	CbGeAlD
Ziprasidone—H1F0—trachea—thyroid cancer	0.00162	0.0331	CbGeAlD
Ziprasidone—DRD3—head—thyroid cancer	0.00157	0.0321	CbGeAlD
Ziprasidone—CHRM1—saliva-secreting gland—thyroid cancer	0.00152	0.0311	CbGeAlD
Ziprasidone—HTR6—head—thyroid cancer	0.00151	0.0309	CbGeAlD
Ziprasidone—DRD5—head—thyroid cancer	0.00147	0.0301	CbGeAlD
Ziprasidone—CHRM3—saliva-secreting gland—thyroid cancer	0.00136	0.0279	CbGeAlD
Ziprasidone—CHRM5—head—thyroid cancer	0.00132	0.027	CbGeAlD
Ziprasidone—H1F0—thyroid gland—thyroid cancer	0.00128	0.0262	CbGeAlD
Ziprasidone—ADRA1B—head—thyroid cancer	0.00121	0.0246	CbGeAlD
Ziprasidone—CHRM1—trachea—thyroid cancer	0.00117	0.024	CbGeAlD
Ziprasidone—H1F0—head—thyroid cancer	0.00114	0.0233	CbGeAlD
Ziprasidone—DRD1—head—thyroid cancer	0.00112	0.023	CbGeAlD
Ziprasidone—HTR3A—head—thyroid cancer	0.00109	0.0222	CbGeAlD
Ziprasidone—HTR2A—neck—thyroid cancer	0.00104	0.0212	CbGeAlD
Ziprasidone—HTR7—trachea—thyroid cancer	0.001	0.0205	CbGeAlD
Ziprasidone—ADRA2C—trachea—thyroid cancer	0.000919	0.0188	CbGeAlD
Ziprasidone—HTR1B—head—thyroid cancer	0.00091	0.0186	CbGeAlD
Ziprasidone—CHRM2—head—thyroid cancer	0.000905	0.0185	CbGeAlD
Ziprasidone—HTR1D—head—thyroid cancer	0.000881	0.018	CbGeAlD
Ziprasidone—HTR2C—head—thyroid cancer	0.000873	0.0178	CbGeAlD
Ziprasidone—CHRM3—thyroid gland—thyroid cancer	0.000831	0.017	CbGeAlD
Ziprasidone—SLC6A4—head—thyroid cancer	0.000827	0.0169	CbGeAlD
Ziprasidone—CHRM1—head—thyroid cancer	0.000824	0.0169	CbGeAlD
Ziprasidone—H1F0—lymph node—thyroid cancer	0.000797	0.0163	CbGeAlD
Ziprasidone—HRH1—trachea—thyroid cancer	0.000747	0.0153	CbGeAlD
Ziprasidone—CHRM3—head—thyroid cancer	0.000738	0.0151	CbGeAlD
Ziprasidone—HTR1A—head—thyroid cancer	0.000735	0.015	CbGeAlD
Ziprasidone—ADRA2A—trachea—thyroid cancer	0.000734	0.015	CbGeAlD
Ziprasidone—HTR7—head—thyroid cancer	0.000702	0.0144	CbGeAlD
Ziprasidone—ADRA1A—head—thyroid cancer	0.000677	0.0138	CbGeAlD
Ziprasidone—DRD2—head—thyroid cancer	0.000664	0.0136	CbGeAlD
Ziprasidone—KCNH2—head—thyroid cancer	0.000654	0.0134	CbGeAlD
Ziprasidone—ADRA2C—head—thyroid cancer	0.000645	0.0132	CbGeAlD
Ziprasidone—CYP1A2—thyroid gland—thyroid cancer	0.000631	0.0129	CbGeAlD
Ziprasidone—HTR2A—trachea—thyroid cancer	0.000624	0.0128	CbGeAlD
Ziprasidone—ADRA2A—thyroid gland—thyroid cancer	0.00058	0.0119	CbGeAlD
Ziprasidone—HRH1—head—thyroid cancer	0.000524	0.0107	CbGeAlD
Ziprasidone—ADRA2A—head—thyroid cancer	0.000515	0.0105	CbGeAlD
Ziprasidone—KCNH2—lymph node—thyroid cancer	0.000458	0.00936	CbGeAlD
Ziprasidone—ADRA2C—lymph node—thyroid cancer	0.000452	0.00924	CbGeAlD
Ziprasidone—HTR2A—head—thyroid cancer	0.000438	0.00895	CbGeAlD
Ziprasidone—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000426	0.000995	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000425	0.000991	CcSEcCtD
Ziprasidone—Urticaria—Sorafenib—thyroid cancer	0.000423	0.000988	CcSEcCtD
Ziprasidone—Body temperature increased—Sorafenib—thyroid cancer	0.000421	0.000983	CcSEcCtD
Ziprasidone—Abdominal pain—Sorafenib—thyroid cancer	0.000421	0.000983	CcSEcCtD
Ziprasidone—Renal impairment—Epirubicin—thyroid cancer	0.000421	0.000983	CcSEcCtD
Ziprasidone—Dermatitis bullous—Epirubicin—thyroid cancer	0.000419	0.000979	CcSEcCtD
Ziprasidone—Eczema—Doxorubicin—thyroid cancer	0.000413	0.000963	CcSEcCtD
Ziprasidone—Hypoglycaemia—Epirubicin—thyroid cancer	0.000411	0.000958	CcSEcCtD
Ziprasidone—Lethargy—Epirubicin—thyroid cancer	0.000409	0.000954	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000409	0.000954	CcSEcCtD
Ziprasidone—Hyponatraemia—Epirubicin—thyroid cancer	0.000402	0.000939	CcSEcCtD
Ziprasidone—Renal failure acute—Doxorubicin—thyroid cancer	0.000402	0.000937	CcSEcCtD
Ziprasidone—Diplopia—Epirubicin—thyroid cancer	0.000401	0.000935	CcSEcCtD
Ziprasidone—Osteoarthritis—Epirubicin—thyroid cancer	0.000401	0.000935	CcSEcCtD
Ziprasidone—Pain in extremity—Epirubicin—thyroid cancer	0.000401	0.000935	CcSEcCtD
Ziprasidone—CYP2D6—head—thyroid cancer	0.000399	0.00816	CbGeAlD
Ziprasidone—Increased appetite—Doxorubicin—thyroid cancer	0.000395	0.000921	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000393	0.000917	CcSEcCtD
Ziprasidone—Hypersensitivity—Sorafenib—thyroid cancer	0.000393	0.000916	CcSEcCtD
Ziprasidone—Renal impairment—Doxorubicin—thyroid cancer	0.00039	0.000909	CcSEcCtD
Ziprasidone—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000388	0.000905	CcSEcCtD
Ziprasidone—Face oedema—Epirubicin—thyroid cancer	0.000387	0.000903	CcSEcCtD
Ziprasidone—Asthenia—Sorafenib—thyroid cancer	0.000382	0.000892	CcSEcCtD
Ziprasidone—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00038	0.000887	CcSEcCtD
Ziprasidone—Lethargy—Doxorubicin—thyroid cancer	0.000378	0.000883	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000378	0.000883	CcSEcCtD
Ziprasidone—Ataxia—Epirubicin—thyroid cancer	0.000377	0.000879	CcSEcCtD
Ziprasidone—Blood creatinine increased—Epirubicin—thyroid cancer	0.000375	0.000876	CcSEcCtD
Ziprasidone—Dehydration—Epirubicin—thyroid cancer	0.000373	0.00087	CcSEcCtD
Ziprasidone—Hyponatraemia—Doxorubicin—thyroid cancer	0.000372	0.000869	CcSEcCtD
Ziprasidone—Osteoarthritis—Doxorubicin—thyroid cancer	0.000371	0.000865	CcSEcCtD
Ziprasidone—Diplopia—Doxorubicin—thyroid cancer	0.000371	0.000865	CcSEcCtD
Ziprasidone—Pain in extremity—Doxorubicin—thyroid cancer	0.000371	0.000865	CcSEcCtD
Ziprasidone—Liver function test abnormal—Epirubicin—thyroid cancer	0.00037	0.000863	CcSEcCtD
Ziprasidone—HRH1—lymph node—thyroid cancer	0.000367	0.00751	CbGeAlD
Ziprasidone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000366	0.000854	CcSEcCtD
Ziprasidone—Hypokalaemia—Epirubicin—thyroid cancer	0.000365	0.000851	CcSEcCtD
Ziprasidone—Diarrhoea—Sorafenib—thyroid cancer	0.000365	0.000851	CcSEcCtD
Ziprasidone—Breast disorder—Epirubicin—thyroid cancer	0.000362	0.000845	CcSEcCtD
Ziprasidone—ADRA2A—lymph node—thyroid cancer	0.000361	0.00737	CbGeAlD
Ziprasidone—Nasopharyngitis—Epirubicin—thyroid cancer	0.000358	0.000836	CcSEcCtD
Ziprasidone—Face oedema—Doxorubicin—thyroid cancer	0.000358	0.000835	CcSEcCtD
Ziprasidone—Gastritis—Epirubicin—thyroid cancer	0.000355	0.000828	CcSEcCtD
Ziprasidone—Dizziness—Sorafenib—thyroid cancer	0.000352	0.000823	CcSEcCtD
Ziprasidone—Ataxia—Doxorubicin—thyroid cancer	0.000349	0.000814	CcSEcCtD
Ziprasidone—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000347	0.000811	CcSEcCtD
Ziprasidone—Dysphagia—Epirubicin—thyroid cancer	0.000346	0.000808	CcSEcCtD
Ziprasidone—Influenza—Epirubicin—thyroid cancer	0.000346	0.000808	CcSEcCtD
Ziprasidone—Dehydration—Doxorubicin—thyroid cancer	0.000345	0.000805	CcSEcCtD
Ziprasidone—Eosinophilia—Epirubicin—thyroid cancer	0.000343	0.0008	CcSEcCtD
Ziprasidone—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000342	0.000799	CcSEcCtD
Ziprasidone—Vomiting—Sorafenib—thyroid cancer	0.000339	0.000791	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000339	0.00079	CcSEcCtD
Ziprasidone—Hypokalaemia—Doxorubicin—thyroid cancer	0.000337	0.000788	CcSEcCtD
Ziprasidone—Angina pectoris—Epirubicin—thyroid cancer	0.000337	0.000787	CcSEcCtD
Ziprasidone—Rash—Sorafenib—thyroid cancer	0.000336	0.000784	CcSEcCtD
Ziprasidone—Dermatitis—Sorafenib—thyroid cancer	0.000336	0.000784	CcSEcCtD
Ziprasidone—Breast disorder—Doxorubicin—thyroid cancer	0.000335	0.000782	CcSEcCtD
Ziprasidone—Headache—Sorafenib—thyroid cancer	0.000334	0.000779	CcSEcCtD
Ziprasidone—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000331	0.000774	CcSEcCtD
Ziprasidone—Gastritis—Doxorubicin—thyroid cancer	0.000328	0.000766	CcSEcCtD
Ziprasidone—Dysuria—Epirubicin—thyroid cancer	0.000324	0.000756	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000322	0.000751	CcSEcCtD
Ziprasidone—Dysphagia—Doxorubicin—thyroid cancer	0.00032	0.000748	CcSEcCtD
Ziprasidone—Influenza—Doxorubicin—thyroid cancer	0.00032	0.000748	CcSEcCtD
Ziprasidone—Eosinophilia—Doxorubicin—thyroid cancer	0.000317	0.000741	CcSEcCtD
Ziprasidone—Nausea—Sorafenib—thyroid cancer	0.000316	0.000739	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000316	0.000738	CcSEcCtD
Ziprasidone—Weight increased—Epirubicin—thyroid cancer	0.000315	0.000736	CcSEcCtD
Ziprasidone—Weight decreased—Epirubicin—thyroid cancer	0.000313	0.000731	CcSEcCtD
Ziprasidone—Hyperglycaemia—Epirubicin—thyroid cancer	0.000312	0.000729	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—thyroid cancer	0.000312	0.000729	CcSEcCtD
Ziprasidone—Pneumonia—Epirubicin—thyroid cancer	0.000311	0.000725	CcSEcCtD
Ziprasidone—Infestation NOS—Epirubicin—thyroid cancer	0.000309	0.000721	CcSEcCtD
Ziprasidone—Infestation—Epirubicin—thyroid cancer	0.000309	0.000721	CcSEcCtD
Ziprasidone—Renal failure—Epirubicin—thyroid cancer	0.000304	0.000708	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000303	0.000706	CcSEcCtD
Ziprasidone—Jaundice—Epirubicin—thyroid cancer	0.000301	0.000703	CcSEcCtD
Ziprasidone—Conjunctivitis—Epirubicin—thyroid cancer	0.0003	0.000701	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—thyroid cancer	0.0003	0.000699	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000298	0.000695	CcSEcCtD
Ziprasidone—Sweating—Epirubicin—thyroid cancer	0.000296	0.000691	CcSEcCtD
Ziprasidone—Haematuria—Epirubicin—thyroid cancer	0.000294	0.000687	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000292	0.000683	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—thyroid cancer	0.000292	0.000681	CcSEcCtD
Ziprasidone—Epistaxis—Epirubicin—thyroid cancer	0.000291	0.00068	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—thyroid cancer	0.00029	0.000677	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000289	0.000675	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—thyroid cancer	0.000287	0.000671	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—thyroid cancer	0.000286	0.000667	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—thyroid cancer	0.000286	0.000667	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—thyroid cancer	0.000282	0.000659	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—thyroid cancer	0.000281	0.000656	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00028	0.000654	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—thyroid cancer	0.000279	0.00065	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—thyroid cancer	0.000278	0.00065	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—thyroid cancer	0.000278	0.000649	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—thyroid cancer	0.000278	0.000648	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—thyroid cancer	0.000277	0.000647	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—thyroid cancer	0.000277	0.000647	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—thyroid cancer	0.000276	0.000644	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—thyroid cancer	0.000275	0.000642	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—thyroid cancer	0.000274	0.000639	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—thyroid cancer	0.000274	0.000639	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—thyroid cancer	0.000273	0.000637	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—thyroid cancer	0.000272	0.000636	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—thyroid cancer	0.000272	0.000636	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—thyroid cancer	0.000272	0.000634	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—thyroid cancer	0.000269	0.000629	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—thyroid cancer	0.000267	0.000624	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—thyroid cancer	0.000261	0.000609	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—thyroid cancer	0.000259	0.000605	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—thyroid cancer	0.000258	0.000603	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—thyroid cancer	0.000258	0.000602	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—thyroid cancer	0.000257	0.0006	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—thyroid cancer	0.000257	0.0006	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—thyroid cancer	0.000256	0.000599	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—thyroid cancer	0.000256	0.000599	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000255	0.000596	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—thyroid cancer	0.000255	0.000594	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000253	0.000591	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—thyroid cancer	0.000253	0.00059	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000252	0.000588	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—thyroid cancer	0.000251	0.000587	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—thyroid cancer	0.000251	0.000587	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—thyroid cancer	0.00025	0.000584	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—thyroid cancer	0.00025	0.000583	CcSEcCtD
Ziprasidone—Chills—Epirubicin—thyroid cancer	0.000249	0.000581	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—thyroid cancer	0.000248	0.000578	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—thyroid cancer	0.000247	0.000577	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—thyroid cancer	0.000245	0.000572	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—thyroid cancer	0.000243	0.000567	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—thyroid cancer	0.000241	0.000563	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—thyroid cancer	0.000241	0.000563	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—thyroid cancer	0.00024	0.000559	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—thyroid cancer	0.000239	0.000558	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—thyroid cancer	0.000238	0.000556	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—thyroid cancer	0.000238	0.000555	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—thyroid cancer	0.000233	0.000545	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—thyroid cancer	0.000233	0.000543	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—thyroid cancer	0.000232	0.000542	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—thyroid cancer	0.000232	0.000541	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000231	0.00054	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—thyroid cancer	0.00023	0.000537	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—thyroid cancer	0.000229	0.000535	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—thyroid cancer	0.000227	0.000531	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—thyroid cancer	0.000227	0.000529	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—thyroid cancer	0.000225	0.000524	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—thyroid cancer	0.000223	0.000521	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—thyroid cancer	0.000223	0.000521	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—thyroid cancer	0.000223	0.000521	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—thyroid cancer	0.000222	0.000518	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—thyroid cancer	0.00022	0.000514	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—thyroid cancer	0.000217	0.000506	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—thyroid cancer	0.000216	0.000505	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—thyroid cancer	0.000216	0.000504	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—thyroid cancer	0.000216	0.000504	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—thyroid cancer	0.000215	0.000501	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—thyroid cancer	0.000213	0.000498	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—thyroid cancer	0.000212	0.000495	CcSEcCtD
Ziprasidone—Cough—Epirubicin—thyroid cancer	0.000211	0.000491	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—thyroid cancer	0.00021	0.000491	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—thyroid cancer	0.000208	0.000486	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—thyroid cancer	0.000206	0.000482	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—thyroid cancer	0.000205	0.00048	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—thyroid cancer	0.000205	0.00048	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—thyroid cancer	0.000205	0.00048	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—thyroid cancer	0.000205	0.000479	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—thyroid cancer	0.000205	0.000478	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000204	0.000476	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—thyroid cancer	0.000201	0.000469	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—thyroid cancer	0.000201	0.000468	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—thyroid cancer	0.0002	0.000467	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—thyroid cancer	0.0002	0.000466	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—thyroid cancer	0.000199	0.000463	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—thyroid cancer	0.000197	0.000461	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—thyroid cancer	0.000196	0.000458	CcSEcCtD
Ziprasidone—Infection—Epirubicin—thyroid cancer	0.000196	0.000457	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—thyroid cancer	0.000195	0.000455	CcSEcCtD
Ziprasidone—Shock—Epirubicin—thyroid cancer	0.000194	0.000452	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—thyroid cancer	0.000193	0.000451	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—thyroid cancer	0.000193	0.00045	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—thyroid cancer	0.000193	0.00045	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—thyroid cancer	0.000192	0.000449	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—thyroid cancer	0.000191	0.000446	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—thyroid cancer	0.00019	0.000444	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—thyroid cancer	0.00019	0.000444	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—thyroid cancer	0.00019	0.000444	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—thyroid cancer	0.00019	0.000444	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—thyroid cancer	0.000189	0.000442	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000189	0.000441	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—thyroid cancer	0.000188	0.000438	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—thyroid cancer	0.000186	0.000434	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—thyroid cancer	0.000184	0.00043	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—thyroid cancer	0.000184	0.000429	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—thyroid cancer	0.000181	0.000423	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000179	0.000419	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—thyroid cancer	0.000179	0.000418	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—thyroid cancer	0.000179	0.000417	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000178	0.000416	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—thyroid cancer	0.000178	0.000416	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—thyroid cancer	0.000178	0.000415	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—thyroid cancer	0.000177	0.000413	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—thyroid cancer	0.000177	0.000413	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000176	0.000411	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—thyroid cancer	0.000176	0.00041	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—thyroid cancer	0.000175	0.000409	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—thyroid cancer	0.000174	0.000405	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—thyroid cancer	0.000173	0.000405	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—thyroid cancer	0.000171	0.0004	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—thyroid cancer	0.00017	0.000397	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00017	0.000397	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—thyroid cancer	0.00017	0.000396	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—thyroid cancer	0.000168	0.000393	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000166	0.000388	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—thyroid cancer	0.000165	0.000385	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—thyroid cancer	0.000164	0.000382	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—thyroid cancer	0.000162	0.000379	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—thyroid cancer	0.000162	0.000379	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—thyroid cancer	0.000162	0.000378	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000161	0.000376	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—thyroid cancer	0.00016	0.000374	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—thyroid cancer	0.000158	0.00037	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000157	0.000367	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—thyroid cancer	0.000157	0.000367	CcSEcCtD
Ziprasidone—Urticaria—Epirubicin—thyroid cancer	0.000156	0.000365	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—thyroid cancer	0.000156	0.000364	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—thyroid cancer	0.000156	0.000363	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—thyroid cancer	0.000156	0.000363	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—thyroid cancer	0.00015	0.00035	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000149	0.000348	CcSEcCtD
Ziprasidone—Hypersensitivity—Epirubicin—thyroid cancer	0.000145	0.000339	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—thyroid cancer	0.000145	0.000338	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—thyroid cancer	0.000144	0.000336	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—thyroid cancer	0.000144	0.000336	CcSEcCtD
Ziprasidone—Asthenia—Epirubicin—thyroid cancer	0.000141	0.00033	CcSEcCtD
Ziprasidone—Diarrhoea—Epirubicin—thyroid cancer	0.000135	0.000315	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000134	0.000313	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—thyroid cancer	0.000131	0.000305	CcSEcCtD
Ziprasidone—Dizziness—Epirubicin—thyroid cancer	0.00013	0.000304	CcSEcCtD
Ziprasidone—Vomiting—Epirubicin—thyroid cancer	0.000125	0.000292	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—thyroid cancer	0.000125	0.000291	CcSEcCtD
Ziprasidone—Rash—Epirubicin—thyroid cancer	0.000124	0.00029	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—thyroid cancer	0.000124	0.00029	CcSEcCtD
Ziprasidone—Headache—Epirubicin—thyroid cancer	0.000123	0.000288	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—thyroid cancer	0.00012	0.000281	CcSEcCtD
Ziprasidone—Nausea—Epirubicin—thyroid cancer	0.000117	0.000273	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—thyroid cancer	0.000116	0.00027	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—thyroid cancer	0.000115	0.000268	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—thyroid cancer	0.000115	0.000268	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—thyroid cancer	0.000114	0.000266	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—thyroid cancer	0.000108	0.000253	CcSEcCtD
Ziprasidone—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	1.42e-05	0.00011	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—PTEN—thyroid cancer	1.42e-05	0.00011	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—HRAS—thyroid cancer	1.42e-05	0.00011	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—HRAS—thyroid cancer	1.41e-05	0.000109	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—NRAS—thyroid cancer	1.41e-05	0.000109	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	1.41e-05	0.000109	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	1.41e-05	0.000108	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—PTEN—thyroid cancer	1.4e-05	0.000108	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—HRAS—thyroid cancer	1.4e-05	0.000108	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CCND1—thyroid cancer	1.39e-05	0.000107	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—AKT1—thyroid cancer	1.39e-05	0.000107	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	1.39e-05	0.000107	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PPARG—thyroid cancer	1.38e-05	0.000107	CbGpPWpGaD
Ziprasidone—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	1.38e-05	0.000106	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—BRAF—thyroid cancer	1.37e-05	0.000106	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—AKT1—thyroid cancer	1.37e-05	0.000105	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	1.36e-05	0.000105	CbGpPWpGaD
Ziprasidone—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	1.36e-05	0.000105	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—BRAF—thyroid cancer	1.35e-05	0.000104	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—BRAF—thyroid cancer	1.35e-05	0.000104	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PTEN—thyroid cancer	1.34e-05	0.000104	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—BRAF—thyroid cancer	1.34e-05	0.000103	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—BRAF—thyroid cancer	1.34e-05	0.000103	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—NRAS—thyroid cancer	1.33e-05	0.000102	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CCND1—thyroid cancer	1.33e-05	0.000102	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—BRAF—thyroid cancer	1.33e-05	0.000102	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—NRAS—thyroid cancer	1.33e-05	0.000102	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	1.32e-05	0.000102	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—RXRA—thyroid cancer	1.32e-05	0.000102	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—NRAS—thyroid cancer	1.32e-05	0.000101	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—thyroid cancer	1.32e-05	0.000101	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PTEN—thyroid cancer	1.31e-05	0.000101	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—AKT1—thyroid cancer	1.31e-05	0.000101	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CCND1—thyroid cancer	1.31e-05	0.000101	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	1.31e-05	0.000101	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTGS2—thyroid cancer	1.29e-05	9.97e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—NRAS—thyroid cancer	1.29e-05	9.94e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.28e-05	9.88e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PTEN—thyroid cancer	1.28e-05	9.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PTEN—thyroid cancer	1.27e-05	9.82e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—NRAS—thyroid cancer	1.27e-05	9.78e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PTEN—thyroid cancer	1.26e-05	9.73e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—HRAS—thyroid cancer	1.26e-05	9.71e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—HRAS—thyroid cancer	1.26e-05	9.69e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—KRAS—thyroid cancer	1.26e-05	9.68e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—AKT1—thyroid cancer	1.26e-05	9.67e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—NRAS—thyroid cancer	1.25e-05	9.65e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—AKT1—thyroid cancer	1.25e-05	9.63e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.24e-05	9.53e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—KRAS—thyroid cancer	1.23e-05	9.51e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—AKT1—thyroid cancer	1.23e-05	9.5e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—KRAS—thyroid cancer	1.23e-05	9.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	1.23e-05	9.47e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—KRAS—thyroid cancer	1.23e-05	9.45e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—AKT1—thyroid cancer	1.23e-05	9.44e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	1.22e-05	9.37e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—KRAS—thyroid cancer	1.21e-05	9.35e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.21e-05	9.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	1.21e-05	9.33e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.21e-05	9.33e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—NRAS—thyroid cancer	1.2e-05	9.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTGS2—thyroid cancer	1.19e-05	9.14e-05	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-05	9.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CCND1—thyroid cancer	1.18e-05	9.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	1.18e-05	9.07e-05	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-05	9.07e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	1.16e-05	8.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	1.14e-05	8.82e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—NRAS—thyroid cancer	1.14e-05	8.8e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.14e-05	8.8e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KRAS—thyroid cancer	1.14e-05	8.79e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.14e-05	8.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PTEN—thyroid cancer	1.14e-05	8.79e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.13e-05	8.74e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KRAS—thyroid cancer	1.13e-05	8.73e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTEN—thyroid cancer	1.13e-05	8.69e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—NRAS—thyroid cancer	1.13e-05	8.68e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	1.13e-05	8.68e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	1.12e-05	8.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—AKT1—thyroid cancer	1.11e-05	8.57e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—AKT1—thyroid cancer	1.11e-05	8.56e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.11e-05	8.55e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	1.1e-05	8.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.1e-05	8.48e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.1e-05	8.44e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KRAS—thyroid cancer	1.09e-05	8.42e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.09e-05	8.38e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	1.09e-05	8.37e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KRAS—thyroid cancer	1.08e-05	8.3e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.07e-05	8.28e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.07e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—HRAS—thyroid cancer	1.07e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	1.07e-05	8.21e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.05e-05	8.1e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—HRAS—thyroid cancer	1.05e-05	8.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	1.05e-05	8.08e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—HRAS—thyroid cancer	1.05e-05	8.05e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—HRAS—thyroid cancer	1.04e-05	8.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	1.04e-05	8.01e-05	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	1.04e-05	8e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTEN—thyroid cancer	1.04e-05	7.97e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—HRAS—thyroid cancer	1.03e-05	7.95e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KRAS—thyroid cancer	1.03e-05	7.95e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	1.03e-05	7.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	1.02e-05	7.88e-05	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.02e-05	7.87e-05	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	1.02e-05	7.86e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—RXRA—thyroid cancer	1.02e-05	7.84e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NRAS—thyroid cancer	1.02e-05	7.84e-05	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—AKT1—thyroid cancer	1.02e-05	7.83e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—thyroid cancer	1.02e-05	7.82e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—thyroid cancer	1.01e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—AKT1—thyroid cancer	1.01e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—thyroid cancer	1.01e-05	7.76e-05	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—AKT1—thyroid cancer	1e-05	7.73e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCND1—thyroid cancer	1e-05	7.72e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	1e-05	7.71e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—thyroid cancer	9.87e-06	7.6e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCND1—thyroid cancer	9.86e-06	7.59e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCND1—thyroid cancer	9.83e-06	7.58e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KRAS—thyroid cancer	9.83e-06	7.58e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PPARG—thyroid cancer	9.83e-06	7.57e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NRAS—thyroid cancer	9.82e-06	7.57e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCND1—thyroid cancer	9.8e-06	7.55e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NRAS—thyroid cancer	9.77e-06	7.53e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCND1—thyroid cancer	9.77e-06	7.53e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HRAS—thyroid cancer	9.71e-06	7.48e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—thyroid cancer	9.71e-06	7.48e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—thyroid cancer	9.7e-06	7.47e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HRAS—thyroid cancer	9.7e-06	7.47e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCND1—thyroid cancer	9.68e-06	7.46e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTEN—thyroid cancer	9.67e-06	7.45e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	9.65e-06	7.44e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HRAS—thyroid cancer	9.64e-06	7.42e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—thyroid cancer	9.58e-06	7.38e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	9.56e-06	7.37e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—thyroid cancer	9.51e-06	7.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	9.51e-06	7.32e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—thyroid cancer	9.49e-06	7.31e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—thyroid cancer	9.49e-06	7.31e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—thyroid cancer	9.46e-06	7.29e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—thyroid cancer	9.43e-06	7.27e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—thyroid cancer	9.43e-06	7.27e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—thyroid cancer	9.43e-06	7.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	9.36e-06	7.21e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—thyroid cancer	9.34e-06	7.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	9.31e-06	7.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	9.3e-06	7.16e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—thyroid cancer	9.28e-06	7.15e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	9.28e-06	7.15e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—thyroid cancer	9.26e-06	7.13e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—thyroid cancer	9.23e-06	7.11e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—thyroid cancer	9.2e-06	7.09e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—thyroid cancer	9.17e-06	7.07e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—thyroid cancer	9.16e-06	7.06e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—thyroid cancer	9.11e-06	7.02e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	9.09e-06	7e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	8.97e-06	6.91e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—thyroid cancer	8.77e-06	6.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—thyroid cancer	8.76e-06	6.75e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—thyroid cancer	8.74e-06	6.73e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	8.65e-06	6.67e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NRAS—thyroid cancer	8.63e-06	6.65e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—thyroid cancer	8.62e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—thyroid cancer	8.57e-06	6.61e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—thyroid cancer	8.56e-06	6.6e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—thyroid cancer	8.51e-06	6.55e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NRAS—thyroid cancer	8.49e-06	6.54e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NRAS—thyroid cancer	8.47e-06	6.52e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—thyroid cancer	8.46e-06	6.51e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	8.44e-06	6.51e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NRAS—thyroid cancer	8.44e-06	6.5e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NRAS—thyroid cancer	8.41e-06	6.48e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—thyroid cancer	8.41e-06	6.48e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—thyroid cancer	8.36e-06	6.44e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NRAS—thyroid cancer	8.33e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—thyroid cancer	8.33e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—thyroid cancer	8.33e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	8.31e-06	6.4e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—thyroid cancer	8.25e-06	6.35e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—thyroid cancer	8.2e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	8.18e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—thyroid cancer	8.09e-06	6.23e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	8.05e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—thyroid cancer	7.78e-06	6e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—thyroid cancer	7.74e-06	5.97e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—thyroid cancer	7.73e-06	5.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	7.72e-06	5.95e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—thyroid cancer	7.56e-06	5.83e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—thyroid cancer	7.52e-06	5.79e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—thyroid cancer	7.48e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—thyroid cancer	7.45e-06	5.74e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—thyroid cancer	7.42e-06	5.72e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—thyroid cancer	7.38e-06	5.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—thyroid cancer	7.34e-06	5.66e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—thyroid cancer	7.3e-06	5.63e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—thyroid cancer	7.29e-06	5.62e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—thyroid cancer	7.28e-06	5.61e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—thyroid cancer	7.27e-06	5.6e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—thyroid cancer	7.27e-06	5.6e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—thyroid cancer	7.24e-06	5.58e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—thyroid cancer	7.19e-06	5.54e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—thyroid cancer	7.17e-06	5.53e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—thyroid cancer	7.16e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	7.15e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—thyroid cancer	7.15e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	6.95e-06	5.36e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	6.84e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—thyroid cancer	6.74e-06	5.2e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	6.65e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—thyroid cancer	6.6e-06	5.08e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—thyroid cancer	6.57e-06	5.06e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—thyroid cancer	6.55e-06	5.05e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—thyroid cancer	6.5e-06	5.01e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—thyroid cancer	6.49e-06	5e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—thyroid cancer	6.48e-06	4.99e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—thyroid cancer	6.46e-06	4.98e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—thyroid cancer	6.44e-06	4.96e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—thyroid cancer	6.43e-06	4.95e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—thyroid cancer	6.37e-06	4.91e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—thyroid cancer	6.36e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—thyroid cancer	6.35e-06	4.89e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—thyroid cancer	6.31e-06	4.86e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—thyroid cancer	6.31e-06	4.86e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—thyroid cancer	6.21e-06	4.78e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—thyroid cancer	6.2e-06	4.77e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—thyroid cancer	6.18e-06	4.76e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—thyroid cancer	6.16e-06	4.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	6.14e-06	4.73e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—thyroid cancer	6.1e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	6.08e-06	4.68e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	6.04e-06	4.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—thyroid cancer	5.97e-06	4.6e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—thyroid cancer	5.91e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—thyroid cancer	5.71e-06	4.4e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	5.65e-06	4.35e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—thyroid cancer	5.57e-06	4.29e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—thyroid cancer	5.48e-06	4.22e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—thyroid cancer	5.47e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—thyroid cancer	5.47e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—thyroid cancer	5.45e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—thyroid cancer	5.44e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—thyroid cancer	5.38e-06	4.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	5.37e-06	4.14e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.06e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	4.99e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—thyroid cancer	4.41e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—thyroid cancer	3.89e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—thyroid cancer	3.29e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—thyroid cancer	2.54e-06	1.96e-05	CbGpPWpGaD
